albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
== External links == The MEROPS online database for peptidases and their inhibitors: SPP:A22.003, SPPL2a: A22.007, SPPL2b:A22.004, SPPL2c:A22.006, SPPL3:A22.005 UMich Orientation of Proteins in Membranes families/superfamily-178 - Calculated spatial position of type 1 signal peptidase in membrane signal+peptide+peptidase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Some important work IUPAC has done in these fields includes standardizing nucleotide base sequence code names; publishing books for environmental scientists, chemists, and physicists; and improving education in science. IUPAC is also known for standardizing the atomic weights of the elements through one of its oldest standing committees, the Commission on Isotopic Abundances and Atomic Weights (CIAAW).
== Research and career == Dunn-Walters has over a hundred primary research publications. She studies B cell development in disease, and how the immune system changes during ageing. She has developed new characterisation techniques to understand immune responses, including single-cell and repertoire approaches. She discovered IgM memory B cells in the spleen, that the older immune system has a less diverse repertoire of B cells, that there are at least 10 different types of B cells, that different types of B cells may have different repertoires and therefore be responding to different stimuli. She works in collaboration with computer scientists and together they have produced online tools for repertoire analysis. More recently, the development of new tools for distinguishing between productive and sterile transcripts of Ig constant region genes in B cells has shown that B cells become primed for Immunoglobulin class switching in a stage before they actually switch. She is part of the CARINA (Catalyst Reducing Immune Ageing) Network, a collective which looks to understand how ageing impacts the immune system and vice versa. Dunn-Walters has served on grants awarding and strategy committees for funding bodies such as the UK Research and Innovation (UKRI) MRC and BBSRC, Research Council of Norway, Fondazione Cariplo Italy. She is a member of the British Society for Research on Ageing where she has previously served on the board and as Programme Secretary.
Obesity the condition of having more weight than is best. What is best is less easy to determine. At a gross level, insurance company records can define obesity, or increased understanding of optimum levels of fat can define them. Fashion is the least sensible source of a standard for the proper level of fat in a person. Obstetrician a physician specializing in pregnancy and delivery of children. OGTT See: Oral glucose tolerance test. Ophthalmologist a physician specializing in diseases of and treatment of the eyes. Optometrist A person professionally trained to test the eyes and to detect and treat eye problems and some diseases by prescribing and adapting corrective lenses and other optical aids and by suggesting eye exercise programs. Oral glucose tolerance test (OGTT) Oral hypoglycemic agents Pills or capsules that people take to lower the level of glucose (sugar) in the blood. Overt diabetes Diabetes in the person who shows clear sign/s of the disease such as a great thirst and the need to urinate often.
The idea of hexapods being 'terrestrial crustaceans' is relatively recent, coming from a 2005 molecular analysis study. A 2013 study restructured the relationships within Pancrustacea, and first proposed the name Allotriocarida. The most recent study of Allotriocarida in 2019 provides additional evidence suggesting that Hexapoda and Remipedia are likely more closely related to each other than to Cephalocarida or Branchiopoda. As of 2024, the existence of Allotriocarida as a monophyletic group within Pancrustacea is now much more widely accepted than the Atelocerata classification which dates back to the 19th century. This formerly-held belief was that hexapods and myriapods (centipedes, millipedes, etc.) are more closely related to each other than they are to the Multicrustacea, based on morphological similarities in their tracheae, but this proposition has been contradicted by the aforementioned modern molecular phylogenetic studies. The most recent understanding of Allotriocarida, as described in the 2019 study, can be seen in the cladogram below.
Sources: en.wikipedia.org
93Zr is a radioisotope of zirconium with a half-life of 1.61 million years, decaying through emission of a low-energy beta particle. 73% of decays populate an excited state of niobium-93, which decays with a half-life of 13.9 years (almost entirely by internal conversion, emitting no gamma ray) to the stable ground state of 93Nb, while the remaining 27% of decays directly populate the ground state. It is one of the 7 long-lived fission products. The low specific activity and low energy of its radiation limit the radioactive hazards of this isotope, and its insolubility makes it unlikely to escape a waste repository; all these are shared with palladium-107. Nuclear fission produces it at a fission yield of 6.3% (thermal neutron fission of 235U), one of the most abundant fission products. Nuclear reactors usually contain large amounts of zirconium as fuel rod cladding (see zircalloy), and neutron irradiation of 92Zr also produces some 93Zr, though this is limited by 92Zr's low neutron capture cross section of 0.22 barns. Indeed, one of the primary reasons for using zirconium in fuel rod cladding is its low cross section. 93Zr also has a low neutron capture cross section of 0.7 barns. Most fission zirconium consists of other isotopes; the other isotope with a significant neutron absorption cross section is 91Zr with a cross section of 1.24 barns. 93Zr is a less attractive candidate for disposal by nuclear transmutation than are 99Tc and 129I.
== Side effects == Adverse events include hypoglycemia, pruritus (itch), nasopharyngitis, headache, and upper respiratory tract infection. It may also cause joint pain that can be severe and disabling. Like other DDP-4 inhibitors, alogliptin is weight-neutral. A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.
, is the probability, after time t, that there is a base j at a given position, conditional on there being a base i in that position at time 0. When the model is time reversible, this can be performed between any two sequences, even if one is not the ancestor of the other, if you know the total branch length between them. The asymptotic properties of Pij(t) are such that Pij(0) = δij, where δij is the Kronecker delta function. That is, there is no change in base composition between a sequence and itself. At the other extreme,
=== United Democratic Front === Minister le Grange's own view was that the key organisation in the unrest was the UDF, which he alleged was a front for the ANC and had organised the uprising on the ANC's behalf. On 5 October 1984, he told the Transvaal provincial congress of the National Party:When the [UDF's] actions in the republic are judged against its objectives, affiliations, public actions, pronouncements... one can reach no other conclusion but that [it] is pursuing the same revolutionary goals as the banned ANC and South African Communist Party, and is actively promoting a climate of revolution.In November 1988, the Transvaal Division of the Supreme Court endorsed this view upon the conclusion of the Delmas Treason Trial, convicting three UDF leaders – Popo Molefe, Mosiuoa Lekota, and Moss Chikane – of treason for having instigated the uprising on behalf of the UDF and therefore on behalf of the ANC. The Delmas judge argued that the UDF had ensured that the uprising was "preceded by a propaganda campaign of vast magnitude, which not only attacked the new constitution and the exclusion of blacks therefrom, but also encompassed the Black education system and the Black local authorities". Not only the state but also many of the UDF's own supporters assigned the UDF a key role in coordinating the uprising.
minisatellite A region of repetitive, non-coding genomic DNA in which certain DNA motifs (typically 10–60 bases in length) are tandemly repeated (typically 5–50 times). In the human genome, minisatellites occur at more than 1,000 loci, especially in centromeres and telomeres, and exhibit high mutation rates and high variability between individuals. Like the shorter microsatellites, they are classified as variable number tandem repeats (VNTRs) and are a type of satellite DNA.
Sources: en.wikipedia.org
== Etymology == The name derives from the Ancient Greek word πολύς (polus, meaning "many, much") and the word 'phenol' which refers to a chemical structure formed by attachment of an aromatic benzenoid (phenyl) ring to a hydroxyl (-OH) group (hence the -ol suffix). The term "polyphenol" has been in use at least since 1894.
Ukraine's Defense Ministry claimed that May 2024 was the deadliest month for Russia so far in the war, with Russian troop losses allegedly amounting to 38,940 killed, wounded, missing, or captured. They also claimed a record number of 1,160 Russian artillery systems destroyed.
=== Nigeria === In Nigeria, successful student at the end of the training in both academic and professional assessments with respect to the graduation requirements is certified by the respective University, inducted and licensed by the Medical Laboratory Science Council of Nigeria after a successful one-year internship training.
== Selected publications == Mojsov, Svetlana; Merrifield, R. B. (1984–12). "An improved synthesis of crystalline mammalian glucagon". European Journal of Biochemistry. 145 (3): 601–605. doi:10.1111/j.1432-1033.1984.tb08599.x. ISSN 0014–2956. Svetlana Mojsov; Gordon C. Weir; Joel F. Habener (1987). "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas". Journal of Clinical Investigation. 79 (2): 616–619. doi:10.1172/jci112855. PMC 424143. PMID 3543057. Wikidata Q40920945. S Mojsov; G Heinrich; I B Wilson; M Ravazzola; L Orci; J F Habener (1986). "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing". Journal of Biological Chemistry. 261 (25): 11880–11889. doi:10.1016/s0021-9258(18)67324-7. PMID 3528148. Wikidata Q68895656. Nathan, David M; Schreiber, Eric; Fogel, Howard; Mojsov, Svetlana; Habener, Joel F (1992-02-01). "Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects". Diabetes Care. 15 (2): 270–276. doi:10.2337/diacare.15.2.270. ISSN 0149–5992
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.